KRAS mutations occur in 40–45% of metastatic colorectal cancers (mCRC), typically indicating a poorer prognosis, reduced survival (24–39 months), and resistance to anti-EGFR therapies like cetuximab.
Treatment Approach:
While EGFR inhibitors are ineffective, standard of care for KRAS-mutant cases generally involves chemotherapy paired with bevacizumab.
Patterns of Spread:
KRAS mutations are associated with a higher incidence of lung, brain, and bone metastases, rather than only liver metastasis.
Dr. J just said LL appears to be agnostic to KRAS.
...
Treatment Approach:
While EGFR inhibitors are ineffective, standard of care for KRAS-mutant cases generally involves chemotherapy paired with bevacizumab.
Patterns of Spread:
KRAS mutations are associated with a higher incidence of lung, brain, and bone metastases, rather than only liver metastasis.
Dr. J just said LL appears to be agnostic to KRAS.
...
10